124 related articles for article (PubMed ID: 2515233)
21. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
[TBL] [Abstract][Full Text] [Related]
22. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
23. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
[TBL] [Abstract][Full Text] [Related]
24. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.
Giovarelli M; Santoni A; Jemma C; Musso T; Giuffrida AM; Cavallo G; Landolfo S; Forni G
J Immunol; 1988 Oct; 141(8):2831-6. PubMed ID: 3139768
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptor-dependent IL-12 production by dendritic cells is required for activation of natural killer cell-mediated Type-1 immunity induced by Chrysanthemum coronarium L.
Tanaka S; Koizumi S; Masuko K; Makiuchi N; Aoyagi Y; Quivy E; Mitamura R; Kano T; Ohkuri T; Wakita D; Chamoto K; Kitamura H; Nishimura T
Int Immunopharmacol; 2011 Feb; 11(2):226-32. PubMed ID: 21144920
[TBL] [Abstract][Full Text] [Related]
26. Studies of the enhancement of natural cytotoxicity by the streptococcal immunopotentiator OK432.
Christmas SE; Meager A; Moore M
Int J Immunopharmacol; 1986; 8(1):83-92. PubMed ID: 2420735
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
[TBL] [Abstract][Full Text] [Related]
28. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
Bohn E; Autenrieth IB
J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
[TBL] [Abstract][Full Text] [Related]
29. Natural killer activity in cloned cytotoxic T lymphocytes: regulation by interleukin 2, interferon, and specific antigen.
Brooks CG; Holscher M; Urdal D
J Immunol; 1985 Aug; 135(2):1145-52. PubMed ID: 2409140
[TBL] [Abstract][Full Text] [Related]
30. Enhanced generation of OK-432-induced killer cells by interleukin 2.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):183-8. PubMed ID: 3500332
[TBL] [Abstract][Full Text] [Related]
31. IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens.
Hunter CA; Chizzonite R; Remington JS
J Immunol; 1995 Nov; 155(9):4347-54. PubMed ID: 7594594
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer.
Hunter CA; Timans J; Pisacane P; Menon S; Cai G; Walker W; Aste-Amezaga M; Chizzonite R; Bazan JF; Kastelein RA
Eur J Immunol; 1997 Nov; 27(11):2787-92. PubMed ID: 9394800
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-2 (IL-2) activated natural killer (A-NK) cells: binding to microvascular endothelial cells and BRM enhancement of cytolytic activity.
Brunson KW; Ohashi M; Miller CA; Kitson RP; Basse PH; Goldfarb RH
In Vivo; 1994; 8(1):71-5. PubMed ID: 8054514
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
35. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro.
Ghoneum M; Jewett A
Cancer Detect Prev; 2000; 24(4):314-24. PubMed ID: 11059563
[TBL] [Abstract][Full Text] [Related]
36. Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.
Yamaue H; Katsumi M; Tabuse K; Tabuse Y; Kuribayashi K; Nishihara T; Saito K
Cancer Immunol Immunother; 1987; 25(3):169-74. PubMed ID: 3315203
[TBL] [Abstract][Full Text] [Related]
37. Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice.
Yamaue H; Tanimura H; Iwahashi M; Tsunoda T; Tani M; Inoue M
Biotherapy; 1990; 2(1):51-61. PubMed ID: 2400628
[TBL] [Abstract][Full Text] [Related]
38. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.
Perussia B; Chan SH; D'Andrea A; Tsuji K; Santoli D; Pospisil M; Young D; Wolf SF; Trinchieri G
J Immunol; 1992 Dec; 149(11):3495-502. PubMed ID: 1358972
[TBL] [Abstract][Full Text] [Related]
39. Effects of interleukin-2, OK-432 and interferon-gamma on in vitro induction of nonspecific killer cells by concanavalin A in mice.
Mizushima Y; Iwata M; Sato M; Yano S
Tohoku J Exp Med; 1986 Jan; 148(1):79-85. PubMed ID: 3085284
[TBL] [Abstract][Full Text] [Related]
40. The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells.
Kurosawa S; Harada M; Shinomiya Y; Terao H; Nomoto K
Cancer Immunol Immunother; 1996 Sep; 43(1):31-8. PubMed ID: 8917633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
